Alnylam Pharmaceuticals Files 8-K Report
Ticker: ALNY · Form: 8-K · Filed: Sep 10, 2025 · CIK: 1178670
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
Alnylam filed an 8-K on 9/10 for events on 9/8. Standard disclosure.
AI Summary
On September 10, 2025, Alnylam Pharmaceuticals, Inc. filed an 8-K report detailing other events and financial statements. The report was filed as of September 10, 2025, with the earliest event reported on September 8, 2025. The company is incorporated in Delaware and headquartered in Cambridge, MA.
Why It Matters
This filing indicates routine corporate reporting and disclosure of events and financial information by Alnylam Pharmaceuticals, Inc. to the SEC.
Risk Assessment
Risk Level: low — This is a standard 8-K filing for corporate events and financial disclosures, not indicating any immediate or significant risks.
Key Players & Entities
- Alnylam Pharmaceuticals, Inc. (company) — Registrant
- September 10, 2025 (date) — Filing Date
- September 8, 2025 (date) — Earliest Event Reported Date
- Cambridge, MA (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is for reporting 'Other Events' and 'Financial Statements and Exhibits' as per SEC regulations.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on September 8, 2025.
What is Alnylam Pharmaceuticals, Inc.'s principal executive office location?
Alnylam Pharmaceuticals, Inc.'s principal executive offices are located at 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142.
What is the company's state of incorporation?
Alnylam Pharmaceuticals, Inc. is incorporated in Delaware.
What is the SEC file number for Alnylam Pharmaceuticals, Inc.?
The SEC file number for Alnylam Pharmaceuticals, Inc. is 001-36407.
Filing Stats: 577 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-09-10 07:30:33
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value per share ALNY The Nasdaq
Filing Documents
- d72540d8k.htm (8-K) — 25KB
- d72540dex991.htm (EX-99.1) — 17KB
- d72540dex992.htm (EX-99.2) — 18KB
- g72540g0909111823634.jpg (GRAPHIC) — 3KB
- 0001193125-25-199686.txt ( ) — 189KB
- alny-20250908.xsd (EX-101.SCH) — 3KB
- alny-20250908_lab.xml (EX-101.LAB) — 18KB
- alny-20250908_pre.xml (EX-101.PRE) — 11KB
- d72540d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release relating to the Convertible Note Offering issued by Alnylam Pharmaceuticals, Inc. on September 8, 2025. 99.2 Press release relating to the Convertible Note Offering issued by Alnylam Pharmaceuticals, Inc. on September 9, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 10, 2025 ALNYLAM PHARMACEUTICALS, INC. By: /s/ Jeffrey V. Poulton Jeffrey V. Poulton Executive Vice President, Chief Financial Officer